

Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

24. (Previously Presented) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) amino acid residues 1 to 300 of SEQ ID NO:2;
- (b) amino acid residues 2 to 300 of SEQ ID NO:2;
- (c) amino acid residues 31 to 300 of SEQ ID NO:2; and
- (d) amino acid residues 31 to 283 of SEQ ID NO:2.

25. (Previously Presented) The isolated polypeptide of claim 24 which comprises the amino acid sequence of (a).

26. (Previously Presented) The isolated polypeptide of claim 24 which comprises the amino acid sequence of (b).

27. (Previously Presented) The isolated polypeptide of claim 24 which comprises the amino acid sequence of (c).

28. (Previously Presented) The isolated polypeptide of claim 24 which comprises the amino acid sequence of (d).

29. (Previously Presented) The isolated polypeptide of claim 24 which comprises a heterologous polypeptide.

30. (Previously Presented) The isolated polypeptide of claim 29, wherein the heterologous polypeptide is an Fc domain of immunoglobulin.

31. (Previously Presented) The isolated polypeptide of claim 24, wherein the polypeptide is glycosylated.

32. (Previously Presented) The isolated polypeptide of claim 24, wherein the polypeptide is pegylated.

33. (Previously Presented) A composition comprising the isolated polypeptide of claim 24.

34. (Previously Presented) The composition of claim 33 which comprises a liposome.

35. (Previously Presented) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of the full-length polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 97810;

(b) the amino acid sequence of the full-length polypeptide excluding the N-terminal methionine residue encoded by the cDNA clone contained in ATCC Deposit No. 97810;

(c) the amino acid sequence of the mature polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 97810; and

(d) the amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 97810.

36. (Previously Presented) The polypeptide of claim 35 which comprises the amino acid sequence of (a).

37. (Previously Presented) The polypeptide of claim 35 which comprises the amino acid sequence of (b).

38. (Previously Presented) The polypeptide of claim 35 which comprises the amino acid sequence of (c).

39. (Previously Presented) The polypeptide of claim 35 which comprises the amino acid sequence of (d).
40. (Previously Presented) The isolated polypeptide of claim 39 which comprises a heterologous polypeptide.
41. (Previously Presented) The isolated polypeptide of claim 40 wherein the heterologous polypeptide is an Fc domain of immunoglobulin.
42. (Previously Presented) The isolated polypeptide of claim 39, wherein the polypeptide is glycosylated.
43. (Previously Presented) The isolated polypeptide of claim 39, wherein the polypeptide is pegylated.
44. (Previously Presented) A composition comprising the isolated polypeptide of claim 39.
45. (Previously Presented) The composition of claim 44 which comprises a liposome.
46. (Currently Amended) An isolated polypeptide comprising an amino acid sequence 90% or more identical to an amino acid sequence selected from the group consisting of:
- (a) amino acid residues 1 to 300 of SEQ ID NO:2;
 - (b) amino acid residues 2 to 300 of SEQ ID NO:2;
 - (c) amino acid residues 31 to 300 of SEQ ID NO:2; and
 - (d) amino acid residues 31 to 283 of SEQ ID NO:2;
- wherein said polypeptide binds Fas ligand.
47. (Previously Presented) The isolated polypeptide of claim 46 which comprises an amino acid sequence 90% or more identical to the amino acid sequence of (a).

48. (Previously Presented) The isolated polypeptide of claim 46 which comprises an amino acid sequence 90% or more identical to the amino acid sequence of (b).

49. (Previously Presented) The isolated polypeptide of claim 46 which comprises an amino acid sequence 90% or more identical to the amino acid sequence of (c).

50. (Previously Presented) The isolated polypeptide of claim 46 which comprises an amino acid sequence 90% or more identical to the amino acid sequence of (d).

51. (Previously Presented) The isolated polypeptide of claim 46 which comprises an amino acid sequence 95% or more identical to the amino acid sequence of (a).

52. (Previously Presented) The isolated polypeptide of claim 46 which comprises an amino acid sequence 95% or more identical to the amino acid sequence of (b).

53. (Previously Presented) The isolated polypeptide of claim 46 which comprises an amino acid sequence 95% or more identical to amino the amino acid sequence of (c).

54. (Previously Presented) The isolated polypeptide of claim 46 which comprises an amino acid sequence 95% or more identical to the amino acid sequence of (d).

55. (Previously Presented) The isolated polypeptide of claim 50 which comprises a heterologous polypeptide.

56. (Previously Presented) The isolated polypeptide of claim 55 wherein the heterologous polypeptide is an Fc domain of immunoglobulin.

57. (Previously Presented) The isolated polypeptide of claim 50, wherein the polypeptide is glycosylated.

58. (Previously Presented) The isolated polypeptide of claim 50, wherein the polypeptide is pegylated.

59. (Previously Presented) A composition comprising the isolated polypeptide of claim 50.

60. (Previously Presented) The composition of claim 59 which comprises a liposome.

61. (Currently Amended) An isolated polypeptide comprising an amino acid sequence 90% or more identical to an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 97810;

(b) the amino acid sequence of the full-length polypeptide excluding the amino-terminal methionine encoded by the cDNA contained in ATCC Deposit No. 97810.

(c) the amino acid sequence of the mature polypeptide encoded by the cDNA contained in ATCC Deposit No. 97810; and

(d) the amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 97810;

wherein said polypeptide binds Fas ligand.

62. (Previously Presented) The isolated polypeptide of claim 61 which comprises an amino acid sequence 90% or more identical to the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 97810.

63. (Previously Presented) The isolated polypeptide of claim 61 which comprises an amino acid sequence 90% or more identical to the amino acid sequence of the full-length polypeptide excluding the amino-terminal methionine encoded by the cDNA contained in ATCC Deposit No. 97810.

64. (Previously Presented) The isolated polypeptide of claim 61 which comprises an amino acid sequence 90% or more identical to the amino acid sequence of the mature polypeptide encoded by the cDNA contained in ATCC Deposit No. 97810.

65. (Previously Presented) The isolated polypeptide of claim 61 which comprises an amino acid sequence 90% or more identical to the amino acid sequence of the extracellular polypeptide encoded by the cDNA contained in ATCC Deposit No. 97810.

66. (Previously Presented) The isolated polypeptide of claim 61 which comprises an amino acid sequence 95% or more identical to the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 97810.

67. (Previously Presented) The isolated polypeptide of claim 61 which comprises an amino acid sequence 95% or more identical to the amino acid sequence of the full-length polypeptide excluding the amino-terminal methionine encoded by the cDNA contained in ATCC Deposit No. 97810.

68. (Previously Presented) The isolated polypeptide of claim 61 which further comprises an amino acid sequence 95% or more identical to the amino acid sequence of the mature polypeptide encoded by the cDNA contained in ATCC Deposit No. 97810.

69. (Previously Presented) The isolated polypeptide of claim 61 which further comprises an amino acid sequence 95% or more identical to the amino acid sequence of the extracellular polypeptide encoded by the cDNA contained in ATCC Deposit No. 97810.

70. (Previously Presented) The isolated polypeptide of claim 65 which comprises a heterologous polypeptide.

71. (Previously Presented) The isolated polypeptide of claim 70 wherein the heterologous polypeptide is an Fc domain of immunoglobulin.

72. (Previously Presented) The isolated polypeptide of claim 65, wherein the polypeptide is glycosylated.
73. (Previously Presented) The isolated polypeptide of claim 65, wherein the polypeptide is pegylated.
74. (Previously Presented) A composition comprising the isolated polypeptide of claim 65.
75. (Previously Presented) The composition of claim 74 which comprises a liposome.
76. (Currently Amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) amino acid residues m-300 of SEQ ID NO:2, where m is an integer from 1 to 49;
 - (b) amino acid residues 1-y of SEQ ID NO:2, where y is an integer from 193-300; and
 - (c) amino acid residues m-y of SEQ ID NO:2, where m is an integer from 1 to 49 and where y is an integer from 193-300;
- wherein said polypeptide binds Fas Ligand.
77. (Previously Presented) The isolated polypeptide of claim 76 which is an amino acid sequence according to (a).
78. (Previously Presented) The isolated polypeptide of claim 76 which is an amino acid sequence according to (b).
79. (Previously Presented) The isolated polypeptide of claim 76 which is an amino acid sequence according to (c).

80. (Previously Presented) The isolated polypeptide of claim 77 which comprises amino acid residues 49 to 300 of SEQ ID NO:2.

81. (Previously Presented) The isolated polypeptide of claim 78 which comprises amino acid residues 1 to 193 of SEQ ID NO:2.

82. (Previously Presented) The isolated polypeptide of claim 79 which comprises amino acid residues 49 to 193 of SEQ ID NO:2.

83. (Previously Presented) The isolated polypeptide of claim 76 which comprises a heterologous polypeptide.

84. (Previously Presented) The isolated polypeptide of claim 83 wherein the heterologous polypeptide is an Fc domain of immunoglobulin.

85. (Previously Presented) The polypeptide of claim 76, wherein the isolated polypeptide is glycosylated.

86. (Previously Presented) The polypeptide of claim 76, wherein the isolated polypeptide is pegylated.

87. (Previously Presented) A composition comprising the isolated polypeptide of claim 76.

88. (Previously Presented) The composition of claim 87 which comprises a liposome.

89-101. (Cancelled)

102. (Currently Amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) amino acid residues 31 to 46 of SEQ ID NO:2;

- (b) amino acid residues 57 to 117 of SEQ ID NO:2;
- (c) amino acid residues 132 to 175 of SEQ ID NO:2;
- (d) amino acid residues 185 to 194 of SEQ ID NO:2;
- (e) amino acid residues 205 to 217 of SEQ ID NO:2;
- (f) amino acid residues 239 to 264 of SEQ ID NO:2;
- (g) amino acid residues 283 to 298 of SEQ ID NO:2; and
- (h) an epitope bearing fragment of amino acid residues 1 to 300 of SEQ ID NO:2;

wherein said polypeptide binds Fas Ligand.

103. (Previously Presented) The isolated polypeptide of claim 102, wherein the amino acid sequence is (a).

104. (Previously Presented) The isolated polypeptide of claim 102, wherein the amino acid sequence is (b).

105. (Previously Presented) The isolated polypeptide of claim 102, wherein the amino acid sequence is (c).

106. (Previously Presented) The isolated polypeptide of claim 102, wherein the amino acid sequence is (d).

107. (Previously Presented) The isolated polypeptide of claim 102, wherein the amino acid sequence is (e).

108. (Previously Presented) The isolated polypeptide of claim 102, wherein the amino acid sequence is (f).

109. (Previously Presented) The isolated polypeptide of claim 102, wherein the amino acid sequence is (g).

110. (Previously Presented) The isolated polypeptide of claim 102, wherein the amino acid sequence is an amino acid sequence according to (h).
111. (Previously Presented) The isolated polypeptide of claim 102 which comprises a heterologous polypeptide.
112. (Previously Presented) The isolated polypeptide of claim 111 wherein the heterologous polypeptide is an Fc domain of immunoglobulin.
113. (Previously Presented) The isolated polypeptide of claim 102, wherein the polypeptide is glycosylated.
114. (Previously Presented) The isolated polypeptide of claim 102, wherein the polypeptide is pegylated.
115. (Previously Presented) A composition comprising the isolated polypeptide of claim 102.
116. (Previously Presented) The composition of claim 115 which comprises a liposome.
- 117-123. (Cancelled)
124. (Currently Amended) An isolated polypeptide comprising at least 30 contiguous amino acid residues of SEQ ID NO:2 wherein said polypeptide binds Fas Ligand.
125. (Previously Presented) The isolated polypeptide of claim 124 which comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.
126. (Previously Presented) The isolated polypeptide of claim 124 which comprises a heterologous polypeptide.

127. (Previously Presented) The isolated polypeptide of claim 126 wherein the heterologous polypeptide is an Fc domain of immunoglobulin.

128. (Previously Presented) The isolated polypeptide of claim 124, wherein the polypeptide is glycosylated.

129. (Previously Presented) The isolated polypeptide of claim 124, wherein the polypeptide is pegylated.

130. (Previously Presented) A composition comprising the isolated polypeptide of claim 124.

131. (Previously Presented) The composition of claim 130 which comprises a liposome.